Semaglutide


GLP-1 receptor agonist (long-acting)

A long-acting GLP-1 receptor agonist FDA-approved as Ozempic (T2DM) and Wegovy (obesity), with extended duration through albumin-binding and amino acid substitution.

Abstract

Semaglutide (Ozempic, Wegovy, Rybelsus; CAS 910463-68-2; molecular weight 4113.58) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, 2017; Rybelsus oral, 2019) and chronic weight management (Wegovy, 2021). The compound is structurally based on native GLP-1 with two amino acid substitutions (Aib at position 8 to resist DPP-4 cleavage; Arg34Lys) and a fatty acid chain (octadecanoic diacid) attached via a glutamic acid spacer that enables reversible albumin binding for extended plasma half-life (approximately 1 week). Mechanism is GLP-1 receptor agonism producing glucose-dependent insulin release, glucagon suppression, gastric emptying delay, and central satiety effects. The semaglutide STEP program demonstrated 14 to 18 percent weight loss over 68 weeks in obesity trials; cardiovascular outcomes trials demonstrated MACE reduction in T2DM. Schedule status: prescription-only.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph